Company intelligence / Profile preview

Sanquin

Amsterdam, North Holland Province, Netherlandssanquin.org ↗

Ownership: Private
Employees: ~2500
Development stage: Commercial

Overview

Sanquin provides the entire Dutch blood supply chain and develops/produces plasma-derived medicines. It conducts fundamental and applied research in transfusion medicine and immunology. Its products are widely used in hospitals across the Netherlands. The organization also offers diagnostic services with over half a million samples tested annually. No clinical trial results for proprietary drugs are published; its main output consists of established biologics/blood products.

Therapeutic areas: ImmunologyHematology
Modalities: BiologicRecombinant proteinPlasma-derived therapyCell therapyDiagnostic service/testingSmall molecule
Industry: Academic Hospital/University/Research

Partnerships

Academic centers such as Amsterdam University Medical Centre and Leiden University Medical CentreTRIP FoundationNTT DATA Business Solutions

Beyond the preview

Go deeper on Sanquin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sanquin.